Inside HS Inflammation: Why JAK1 Has Become a Target

HS is one of the most clinically heterogeneous diseases in dermatology, and its lesional inflammation is just as varied. Amit Garg, MD, explains why that complexity, which goes beyond TNF-α and IL-17 to a broader network of cytokines, makes a more upstream approach compelling. He describes how JAK inhibition may influence multiple inflammatory signals at once, and why selectivity for JAK1 matters for safety as this investigational strategy is studied in HS.